Search results for " Mabs"
Article
Improving Process-Scale Chromatography
Thermo Fisher has introduced a new platform technology with large-scale production capability based on affinity chromatography resins that address challenges in the purification of mAbs, antibody frag…
Article
USP Publishes Monoclonal Antibody Guidelines
USP standards for mAbs
Currently, licensed monoclonal antibody (mAb) therapeutics include those involved in the activation of effector cells, cell killing, cross-linked induced apoptosis, antagonis…
Article
Leveraging Computational Models of Glycosylation for Biopharma QA
Man5 may also enhance antibody-dependent cellular cytotoxicity (ADCC) (8), a mechanism that improves the oncolytic activity of mAbs.
• Tandem α-1,3 galactose is a non-human glycosylation motif tha…
Article
ADC Development Robust Despite Lackluster Performance
Mersana is generating Fleximer-ADCs using mAbs provided by EMD Serono. Mersana will also conduct drug discovery and pre-clinical development activities, while EMD Serono will be responsible for clinic…
Article
Re-use of Protein A Resin: Fouling and Economics
A typical Protein A chromatography process consists of five steps: pre-equilibration and equilibration of the column; capture of the mAbs from the harvest; wash step with the selective buffer to remov…
Article
Next Generation Process Chromatography
The surface area that Fibro exhibits provides immediate binding opportunities at high capacities of the target proteins such as mAbs. This means that a chromatographic cycle that currently takes ~3 ho…
Article
A Look at the Affinity Chromatography Landscape
He points to engineered antibody affinity resins and mild-pH elution Protein A resins that enable elution of mAbs without the use of traditional, low-pH elution buffers as important examples.
“…
Article
Development of Purification for Challenging Fc-Fusion Proteins
Monoclonal antibody purification processes exist in different well-established platforms with extensive process performance histories for production of commercial mAbs (6-10), which typically consist …
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
Several years ago, we started a development project to design and validate the next-generation protein A resin, MabSelect PrismA, which was just introduced to the market. Now, 1M NaOH can in fact be u…
Article
Process Chromatography Selection for Downstream Processing Applications
Separation Technologies
BioPharm: What are the most commonly used separation technologies for biologics that are not monoclonal antibodies (mAbs)?
Björkman (Cytiva): If one excludes mAbs, then…